18 results match your criteria Current Respiratory Medicine Reviews[Journal]

  • Page 1 of 1

Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis.

Curr Respir Med Rev 2018 Mar;14(1):48-60

1Department of Pathology, Abderrahman Mami Hospital, Ariana, Tunisia; 2University Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia; 3Department of General Surgery B, Charles Nicolle Hospital, Tunis, Tunisia; 4Medical Center of ABM, Military College, Qatar.

Background: The accurate microscopic diagnosis of lung cancer has become insufficient due to the concept of personalized medicine. Tissue samples are used not only for microscopic diagnosis but also for the assessment of the different targets. Biopsies are performed in 80% of the patients and they are not sufficient for molecular diagnosis in 30% of the cases. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/161699/article
Publisher Site
http://dx.doi.org/10.2174/1573398X14666180430144452DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128071PMC
March 2018
35 Reads

An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases.

Curr Respir Med Rev 2017 Mar;13(1):22-29

Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.

Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573398X13666170616110738DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735517PMC
March 2017
10 Reads

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience.

Curr Respir Med Rev 2017 Mar;13(1):36-42

Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.

Background: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. To date, omalizumab is the only biological drug currently licensed as add-on therapy in children aged > 6 years with moderate-to-severe and severe allergic asthma uncontrolled after treatment with high dose of inhaled corticosteroids plus long-acting inhaled beta2-agonist. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573398X13666170426094536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684803PMC
March 2017
11 Reads

Choline Triggers Exacerbations of Chronic Obstructive Pulmonary Disease in Patients Infected with .

Authors:
Sandra Grumelli

Curr Respir Med Rev 2016 ;12(2):167-174

Centro de Investigaciones en Medicina Respiratoria, Universidad Católica de Córdoba, Cordoba, Argentina.

Background: Although exacerbations of chronic obstructive pulmonary disease produced by infections are a major cause of death, the molecular mechanism that produces them is not well known. Here we focused on the energetic basis of dyspnoea, hypercapnia and acidosis symptoms.

Methods And Findings: We used an in vivo exacerbation model exposing mice to cigarette smoke and LPS, to mimic emphysema and infections, and choline challenges to trigger exacerbations, that showed 31% increased in the airway resistance for naïve mice and 250% for smoke/LPS treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573398X12999160506104327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788026PMC
January 2016
12 Reads

Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD).

Curr Respir Med Rev 2015 Jun;11(2):175-183

Tulane University School of Medicine, New Orleans, USA ; New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, USA.

Objective: The impact and natural history of connective tissue disease related interstitial lung disease (CTD-ILD) are poorly understood; and have not been previously described from the patient's perspective. This investigation sought insight into CTD-ILD from the patients' perspective to add to our knowledge of CTD-ILD, identify disease-specific areas of unmet need and gather potentially meaningful information towards development of disease-specific patient-reported outcome measures (PROMs).

Methods: A mixed methods design incorporating patient focus groups (FGs) querying disease progression and life impact followed by questionnaires with items of importance generated by >250 ILD specialists were implemented among CTD-ILD patients with rheumatoid arthritis, idiopathic inflammatory myopathies, systemic sclerosis, and other CTD subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573398X11666150619182624DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643941PMC
June 2015
42 Reads

Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Curr Respir Med Rev 2015;11(2):163-174

New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center; New Orleans, LA, USA; Tulane University Lung Center; New Orleans, LA, USA.

The chronic fibrosing idiopathic interstitial pneumonias (IIPs) are a group of heterogeneous pulmonary parenchymal disorders described by radiologic and histological patterns termed usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP). These include idiopathic pulmonary fibrosis (IPF) and those related to connective tissue disease (CTD) and are associated with substantial morbidity and mortality. Beyond the importance of establishing an appropriate diagnosis, designing optimal clinical trials for IIPs has been fraught with difficulties in consistency of clinical endpoints making power analyses, and the establishment of efficacy and interpretation of results across trials challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573398X11666150619183527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806861PMC
January 2015
41 Reads

Mast Cells in Lung Homeostasis: Beyond Type I Hypersensitivity.

Curr Respir Med Rev 2014 Jun;10(2):115-123

Department of Immunology, National School of Biological Sciences (ENCB), National Polytechnic Institute (IPN), Mexico City, Mexico.

Lungs are indispensable organs for the respiratory process, and maintaining their homeostasis is essential for human health and survival. However, during the lifetime of an individual, the lungs suffer countless insults that put at risk their delicate organization and function. Many cells of the immune system participate to maintain this equilibrium and to keep functional lungs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573398X10666141024220151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255078PMC
June 2014
18 Reads

Recent advances in tuberculosis: New drugs and treatment regimens.

Curr Respir Med Rev 2013 Jun;9(3):200-210

Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, L7 8XP, UK.

The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968807PMC
June 2013
6 Reads

Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics.

Curr Respir Med Rev 2013 Aug;9(4):238-247

Department of Pathology, Medisch Centrum Haaglanden, The Netherlands.

Pleuroparenchymal fibroelastosis (PPFE) is a distinct pattern of pulmonary fibrosis which often runs a rapidly progressive course with a poor prognosis, and it is likely to be introduced as a separate entity in the new classification scheme of idiopathic interstitial pneumonias. It is characterised by pleural fibrosis and subpleural fibroelastosis, with an upper lobe predominance. In addition to cases following lung and bone marrow transplantation, familial and idiopathic cases have been described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573398X113096660025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949414PMC
August 2013
9 Reads

Pleuroparenchymal Fibroelastosis: Its Clinical Characteristics.

Authors:
Kentaro Watanabe

Curr Respir Med Rev 2013 Jun;9:299-237

Department of Respiratory Medicine, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.

Pleuroparenchymal fibroelastosis (PPFE) is a rare pulmonary fibrosis that is clinically characterized by upperlobe predominant fibrosis. PPFE is a slowly progressive disorder and its first symptom is dyspnea or dry cough. Chest pain because of pneumothorax may be the first symptom in some patients. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/openurl/content.php?genre=articl
Publisher Site
http://dx.doi.org/10.2174/1573398X0904140129125307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933942PMC
June 2013
12 Reads

Using Xpert MTB/RIF.

Curr Respir Med Rev 2013 Jun;9:187-192

Division of Medical Microbiology, Department of Clinical Laboratory Sciences, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa ; National Health Laboratory Service, South Africa.

Xpert MTB/RIF is an automated real-time polymerase chain reaction test for simultaneous detection of tuberculosis and rifampicin resistance. Xpert MTB/RIF has demonstrated excellent accuracy in clinical evaluation studies, but has reduced sensitivity for detection of smear-negative tuberculosis. Since sample processing and detection are largely automated, Xpert MTB/RIF is potentially suitable for implementation in resource-limited settings. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/openurl/content.php?genre=articl
Publisher Site
http://dx.doi.org/10.2174/1573398X113099990015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785149PMC
June 2013
5 Reads

Fibrocytes in the Pathogenesis of Chronic Fibrotic Lung Disease.

Curr Respir Med Rev 2013 Feb;9(1):34-41

Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642.

Fibrocytes were initially described in 1999 and since that time there has been a growing body of literature to suggest their importance in a number of chronic lung diseases. It is now well established that fibrocytes derive from the bone marrow and circulate within the peripheral blood. However, when injury occurs, fibrocytes can travel to the site of damage via chemokine-mediated recruitment. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976772PMC
February 2013
7 Reads

Cough and Asthma.

Authors:
Akio Niimi

Curr Respir Med Rev 2011 Feb;7(1):47-54

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.

Cough is the most common complaint for which patients seek medical attention. Cough variant asthma (CVA) is a form of asthma, which presents solely with cough. CVA is one of the most common causes of chronic cough. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/openurl/content.php?genre=articl
Publisher Site
http://dx.doi.org/10.2174/157339811794109327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182093PMC
February 2011
7 Reads

Rhinovirus-associated wheeze during infancy and asthma development.

Curr Respir Med Rev 2011 Jun;7(3):160-166

Department of Pediatrics, Turku University Hospital, Turku, Finland.

Rhinovirus is commonly associated with bronchiolitis - only second to RSV during the first year life. The prevalence of HRV-bronchiolitis may be very high in predisposed infants. HRV diagnosis is almost exclusively based on PCR, which detects respiratory infections with or without symptoms. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469323PMC
June 2011
7 Reads

A Pulmonary Perspective on GASPIDs: Granule-Associated Serine Peptidases of Immune Defense.

Authors:
George H Caughey

Curr Respir Med Rev 2006 Aug;2(39):263-277

The Cardiovascular Research Institute and Department of Medicine, University of California at San Francisco, USA, Northern California Institute for Research and Education, USA, San Francisco Veterans Affairs Medical Center, USA.

Airways are protected from pathogens by forces allied with innate and adaptive immunity. Recent investigations establish critical defensive roles for leukocyte and mast cell serine-class peptidases garrisoned in membrane-bound organelles-here termed Granule-Associated Serine Peptidases of Immune Defense, or GASPIDs. Some better characterized GASPIDs include neutrophil elastase and cathepsin G (which defend against bacteria), proteinase-3 (targeted by antineutrophil antibodies in Wegener's vasculitis), mast cell beta-tryptase and chymase (which promote allergic inflammation), granzymes A and B (which launch apoptosis pathways in infected host cells), and factor D (which activates complement's alternative pathway). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2405921PMC
August 2006
6 Reads

Targeting lung inflammation: novel therapies for the treatment of COPD.

Curr Respir Med Rev 2008 ;4(1):57-68

Department of Environmental Medicine, Lung Biology and Disease Program, University of Rochester Medical Center, Rochester, NY, USA.

Chronic obstructive pulmonary disease (COPD) is a global health problem. As understanding of pathology of COPD has increased it has been established that COPD is associated with the progressive pulmonary inflammation and destruction of lung parenchyma (emphysema) that relate to disease severity. Therefore, it is anticipated that drugs that reduce pulmonary inflammation will provide effective, disease modifying therapy for COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157339808783497873DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723817PMC
January 2008
7 Reads

The Epithelial Cell in Lung Health and Emphysema Pathogenesis.

Curr Respir Med Rev 2006 May;2(2):101-142

Institute of Human Nutrition, Columbia University College of Physicians & Surgeons, Department of Medicine New York, NY 10032, USA.

Cigarette smoking is the primary cause of the irreversible lung disease emphysema. Historically, inflammatory cells such as macrophages and neutrophils have been studied for their role in emphysema pathology. However, recent studies indicate that the lung epithelium is an active participant in emphysema pathogenesis and plays a critical role in the lung's response to cigarette smoke. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721228PMC
May 2006
12 Reads

Bone Marrow-Derived Cells in the Pathogenesis of Lung Fibrosis.

Curr Respir Med Rev 2005;1(1):69-76

Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642, USA.

Progressive pulmonary fibrosis is characterized by failed alveolar reepithelialization and fibroblast/myofibroblast accumulation, with deposition of extracellular matrix. This results in loss of lung elasticity, alveolar collapse and fibrosis, impaired gas exchange and progressive decline in pulmonary function. Myofibroblasts represent an activated, contractile cellular phenotype that are potent producers of collagen and other extracellular matrix proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573398052953613DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975536PMC
January 2005
7 Reads
  • Page 1 of 1